HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

1,2,3,4-tetrahydroquinoline

structure in first source

Also Known As:

tetrahydroquinoline

Networked: 27 relevant articles (3 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - 1,2,3,4-tetrahydroquinoline: 27

Experts

1.	Bello, Martiniano: 2 articles (01/2021 - 01/2019)
2.	Correa-Basurto, José: 2 articles (01/2021 - 01/2019)
3.	Méndez-Luna, David: 2 articles (01/2021 - 01/2019)
4.	Alvaro, Giuseppe: 2 articles (03/2007 - 11/2003)
5.	Barnaby, Robert J: 2 articles (03/2007 - 11/2003)
6.	Bertani, Barbara: 2 articles (03/2007 - 11/2003)
7.	Di Fabio, Romano: 2 articles (03/2007 - 11/2003)
8.	Donati, Daniele: 2 articles (03/2007 - 11/2003)
9.	Pentassuglia, Giorgio: 2 articles (03/2007 - 11/2003)
10.	Ratti, Emiliangelo: 2 articles (03/2007 - 11/2003)

Related Diseases

1.	Lung Neoplasms (Lung Cancer) 12/01/2022 - "A possible efficient substitution of the tetrahydroquinoline scaffold could also be beneficial for the treatment of lung cancer." 12/01/2022 - "Based on previous research findings, tetrahydroquinoline was found to be the most efficient scaffold to be explored for the treatment of lung cancer. " 12/01/2022 - "Tetrahydroquinoline: an efficient scaffold as mTOR inhibitor for the treatment of lung cancer."
2.	Myeloid Leukemia (Leukemia, Myelocytic) 01/01/2021 - "Inhibitors Targeting STAT5 Signaling in Myeloid Leukemias: New Tetrahydroquinoline Derivatives with Improved Antileukemic Potential."
3.	Fragile X Syndrome (Martin Bell Syndrome) 01/01/2021 - "SW-100 (1a), a phenylhydroxamate-based HDAC6 inhibitor (HDAC6i) bearing a tetrahydroquinoline (THQ) capping group, is a highly potent and selective HDAC6i that was shown to be effective in mouse models of Fragile X syndrome and Charcot-Marie-Tooth disease type 2A (CMT2A). "
4.	Type 2A Charcot-Marie-Tooth disease 01/01/2021 - "SW-100 (1a), a phenylhydroxamate-based HDAC6 inhibitor (HDAC6i) bearing a tetrahydroquinoline (THQ) capping group, is a highly potent and selective HDAC6i that was shown to be effective in mouse models of Fragile X syndrome and Charcot-Marie-Tooth disease type 2A (CMT2A). "
5.	Breast Neoplasms (Breast Cancer) 02/01/2011 - "Two tetrahydroquinoline compounds, called DM8 and DM12, from a new series of the cis-2,4-diaryl-r-3-methyl-1,2,3,4-tetrahydroquinolines, were selected for cytotoxic effects studies on cellular lines of human breast cancer. " 01/01/2019 - "Synthesis and In Vitro Evaluation of Tetrahydroquinoline Derivatives as Antiproliferative Compounds of Breast Cancer via Targeting the GPER." 01/01/2019 - "In an effort to develop new therapeutic strategies against breast cancer, we employed an in silico study to explore the binding modes of tetrahydroquinoline 2 and 4 to be compared with the reported ligands G1 and G1PABA. " 01/01/2021 - "Tetrahydroquinoline/4,5-Dihydroisoxazole Molecular Hybrids as Inhibitors of Breast Cancer Resistance Protein (BCRP/ABCG2)."

Related Drugs and Biologics

1.	SW-100
2.	Type 3 Cyclic Nucleotide Phosphodiesterases
3.	Ligands
4.	imidazolone
5.	EMD 60263
6.	Alkaloids
7.	Inflammasomes
8.	Cathepsin L
9.	Cholesterol Ester Transfer Proteins
10.	Neuroprotective Agents